Windtree sells cardiovascular drug candidates to Seismic for $150K upfront plus contingent payments

WINDTREE THERAPEUTICS INC /DE/

Windtree receives $150,000 upfront for its cardiovascular drug candidates, including acute heart failure program.
Windtree is entitled to 20% of future licensing revenue and global commercial net revenue if approved.
If Seismic raises at least $10M, Windtree receives an additional $700,000 payment.
Windtree transfers certain development payables to Seismic as part of the agreement.
The deal includes transfer of intellectual property and the Taiwanese subsidiary to Seismic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.